Company intelligence / Profile preview

Numaferm

Düsseldorf, North Rhine-Westphalia, Germanynumaferm.com ↗

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

Numaferm has demonstrated its technology in over 200 successful projects for more than 50 partners globally. The company provides fast, scalable, cost-efficient recombinant expression of peptides/pepteins/proteins at high quality standards. It operates as a service provider rather than developing its own clinical pipeline. Recent licensing agreement with Zoetis for veterinary therapeutics development. Evonik invested as part of seed financing. No direct clinical results reported since it does not develop proprietary drugs.

Modalities: peptidespepteins (fusion of peptides and proteins)proteins
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

teriparatide

Commercial

Indications: Osteoporosis

Partnerships

Zoetis (animal health/veterinary therapeutics license agreement)PolyPeptide Group (global CDMO partnership)

Beyond the preview

Go deeper on Numaferm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Numaferm.

Explore the full profile